The patient registry software market revenue is expected to reach USD 5,638.3 million by 2030, exhibiting a CAGR of 15.3% during 2024–2030. The demand for health information exchange and population health management is growing rapidly; hence, governments across the world are putting in efforts to digitalize their healthcare systems.
The rising desire for better disease control and patient outcomes, the expanding prevalence of chronic diseases, and the growing emphasis on personalized treatment all contribute to the demand for patient registry software. The market advance is being further stimulated by the increasing adoption of electronic health records (EHR).
Patient registry software improves EHR systems by providing creative tools for data collection, management, and analysis. By letting medical practitioners and academics combine and analyze data from EHRs, clinical trials, surveys, and other sources, it enables the establishment of a comprehensive and centralized registry of persons with certain medical conditions or characteristics.
There are currently more open doors for patient registry software to improve information for the executives, as well as enhance research abilities and patient results, due to the growing use of EHRs. The combination of these two innovations enables a more-exhaustive and -powerful technique for major health events, investigations, and settling on conclusions about medical care.
The need for data-driven healthcare, research, individualized treatment, public health monitoring, regulatory consent, advanced features, and cooperative information sharing is behind the rising demand for patient registry software.
Government organizations have rapidly increased their usage of patient registry software in recent years; therefore, they hold the largest share in this industry. The usefulness of patient registry software for storing and analyzing healthcare data, which results in improved public health outcomes and more-informed policy decisions, is being recognized by government institutions and agencies at both the national and international levels.
Government organizations can follow the recurrence, pervasiveness, and aftereffects of various diseases and problems, as well as find new medical issues and distribute resources more efficiently, by utilizing digital patient registers.
In order to monitor population health management efforts’ results, evaluate the productiveness of healthcare initiatives, and pinpoint areas for improvement, government organizations frequently conduct research studies. By allowing for the collection, processing, and reporting of the data generated during such studies, patient registry software helps researchers carry out their work quickly.
Government organizations can set up continuous observational frameworks to rapidly recognize and answer pandemics, sickness flare-ups, and other general medical problems, by using such IT platforms.
Clinical studies are frequently carried out by pharmaceutical and biotechnology companies to evaluate the benefits and safety of novel medications. By giving them access to a pool of patients with particular diseases, patient registry software can help them discover and enroll qualified participants.
Companies in the pharmaceutical and biotech industries may use patient registry software to collect actual data on patient populations, which may be added to the data on clinical trials. This information may be useful for assessing treatment results, tracking long-term safety, and bolstering regulatory filings.
Pharmaceutical and biotech organizations can more readily grasp infection pervasiveness, territorial contrasts, and patient requests by breaking down patient information. This data can affect their market strategies and promotional efforts. Moreover, firms can work on tackling operational challenges, promoting innovation in healthcare, and utilizing digital health information registers to direct choices about medicine improvement, commercialization, and post-promotion activities.
Some of the key players are IQVIA Inc, IBM Corporation, Optum Inc, Phlexglobal Ltd., Mckesson Corporation, FIGMD Inc., Elekta, Coduent Inc., and Evado Clinical.